![]() |
ProStrakan acquires US commercial rights to Fareston for treatment of metastatic brea
ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.
More... |
| All times are GMT -7. The time now is 09:26 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021